- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06227689
Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China
Evaluation of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination for Middle School Girls in China: a Randomized Controlled Trial and Implementation Science Study
This interventional study targets female students in junior middle school. It goal is to evaluate the effectiveness of a vaccine chatbot on HPV vaccine awareness and vaccination. The main questions it aims to answer are:
- How will the novel digital tool, a vaccine chatbot, impact eligible parents' awareness and knowledge of HPV vaccines, their willingness to vaccinate their daughters, and vaccination status of female students.
- How is the vaccine chatbots accepted by all stakeholders, and what are the facilitators of and barriers to implementing vaccine chatbot promotion campaign.
The intervention group will go through the intervention measure while the control group will not:
- The intervention group will be invited to use the HPV vaccine chatbot online through WeChat , the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the HPV vaccine and get validated answers from the chatbot immediately. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
- The control group will not use the chatbot during the intervention duration.
Researchers will compare participants' HPV vaccine awareness, and vaccination intention and status after intervention between intervention group and control group to evaluate if the vaccine chatbot improves HPV vaccine awareness and vaccination.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a cluster randomized trial consisted of 2 arms to evaluate the effectiveness of a vaccine chatbot on parents' HPV vaccine awareness, knowledge, and vaccination intention and status regarding their daughters in junior middle school.
The sample size was calculated based on two main outcome indicators (parents' willingness to vaccinate, and vaccination rate of female students) and the main analysis method (comparison of differences in rates or means before and after the intervention). 1) According to the literature review, the willingness of Chinese parents to vaccinate their children against HPV is 50%-70%, and the investigators assumed that the willingness to vaccinate was 60% before the intervention and could be increased to 70% after the intervention. The minimum sample size was calculated to be 530 participants in each group, with significance level (α) at 0.05, test power (1-β) of 0.8, and the cluster design effect (D) of 1.5. 2) The current HPV vaccination rate of female students is around 5%, and the investigators assumed that the vaccination rate could increase to 10%-12% after the intervention. The minimum sample size was calculated to be 369-648 participants in each group, with significance level (α) at 0.05, test power (1-β) of 0.8, and the cluster design effect (D) of 1.5.
Multi-stage sampling will be employed. Firstly, three representative cities will be selected to represent the megacity, general urban city, and rural counties in China, respectively. Then, within each city, three or four middle schools will be selected based on economic development, school size, geographical location. Next, around six classes will be randomly selected for each of the three grades in each middle school. For all the female students who have not be vaccinated against HPV in selected classes, one of their parents will be included in the study. A total of around 162 classes are expected to be included, with around 54 classes in each city.
Stratified cluster randomized grouping will be employed. All classes will be grouped into intervention group or control group by class at a 1:1 ratio, stratified by city, school, and grades, resulting with around 81 classes into the intervention group and 81 in control group. Approximately 600 parents (300 in intervention group; 300 in control group) are expected to participate in the study in each city, with a total sample size of 1,800 parents, meeting the sample size requirement.
Baseline survey will be conducted before the intervention. Then, the intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get validated answers from the chatbot immediately. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention. The control group will not use the chatbot during the intervention duration. After 2 weeks, follow-up survey will then be conducted. HPV vaccination status of female students will be collected after 1.5 months and 3 months.
The Difference-in-Differences (DID) method will be utilized to adjust and reduce the effects of other covariates, aiming to evaluate the intervention effect of the chatbot.
Besides impact evaluation, this study will also conduct an implementation science study, using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to comprehensively assess the cost-effectiveness, applicability, and scalability of the HPV vaccine chatbot intervention in real-world. Both quantitative and qualitative methods will be used to evaluate its implementation across the above-mentioned five dimensions: reach, effectiveness, adoption, implementation, and maintenance.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zhiyuan Hou, PhD
- Phone Number: 86+21 33563935
- Email: zyhou@fudan.edu.cn
Study Contact Backup
- Name: Zhiqiang Qu, BS
- Email: zqqu21@m.fudan.edu.cn
Study Locations
-
-
Anhui
-
Chizhou, Anhui, China, 247100
- Chizhou Health Center for Disease Control and Prevention
-
Contact:
- Liuing Gong, MS
- Email: chzcpdcxf@126.com
-
-
Shanghai
-
Shanghai, Shanghai, China
- Jiading District Center for Disease Control and Prevention
-
Contact:
- Hui Peng, MS
- Email: penny200210108@sina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Parents of female students in middle school;
- The students not vaccinated or appointed for HPV vaccination and without contraindications to HPV vaccines;
- Without mental disorders or visual/reading impairments, and able to cooperate with and undergo the intervention activities;
- Obtained informed consent and willing to participate in the study.
Exclusion Criteria:
- Students vaccinated or appointed for HPV vaccination or with any contraindication to HPV vaccines;
- With mental disorders or visual/reading impairments, and unable to cooperate with and undergo the intervention activities;
- Unwilling to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HPV Chatbot Intervention group
In this arm, participants will receive a vaccine chatbot intervention.
They will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get immediate answers from the chatbot.
The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
|
The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately.
All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts.
The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
|
No Intervention: Control group
The control group will not use the chatbot during the intervention duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccination intention
Time Frame: Two weeks between baseline and follow-up surveys
|
Parents' willingness to vaccinate their daughters against HPV, measured using a five-point Likert scale from "very unwilling" to "very willing"
|
Two weeks between baseline and follow-up surveys
|
HPV vaccination status and appointment
Time Frame: 1.5 and 3 months following baseline survey
|
whether participants' daughters get vaccinated against HPV or have an appointment for vaccination, measured by self-report and validated by vaccination information system
|
1.5 and 3 months following baseline survey
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccine awareness and knowledge
Time Frame: Two weeks between baseline and follow-up surveys
|
10 questions about HPV vaccine knowledge and misinformation.
Total knowledge score is calculated based on the number of questions answered correctly by the participants.
|
Two weeks between baseline and follow-up surveys
|
HPV vaccine confidence
Time Frame: Two weeks between baseline and follow-up surveys
|
Vaccine Confidence Index (VCI), including confidence on vaccine importance, effectiveness and safety
|
Two weeks between baseline and follow-up surveys
|
Vaccination delay
Time Frame: Two weeks between baseline and follow-up surveys
|
Whether parents will wait for 9-valent vaccine and delay vaccinating daughter when supply of the 9-valent vaccine runs low
|
Two weeks between baseline and follow-up surveys
|
Chatbot Usability
Time Frame: Two weeks after the follow-up survey
|
Chatbot Usability Questionnaire (CUQ) designed by the Ulster University, measuring Chatbot Personality, Onboarding, User Experience, Error Handling, and so on
|
Two weeks after the follow-up survey
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Zhiyuan Hou, PhD, School of Public Health,Fudan University
Publications and helpful links
General Publications
- Hu S, Xu X, Zhang Y, Liu Y, Yang C, Wang Y, Wang Y, Yu Y, Hong Y, Zhang X, Bian R, Cao X, Xu L, Zhao F. A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China. Vaccine. 2021 Jan 3;39(1):35-44. doi: 10.1016/j.vaccine.2020.11.029. Epub 2020 Nov 23.
- Falcaro M, Castanon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Dec 4;398(10316):2084-2092. doi: 10.1016/S0140-6736(21)02178-4. Epub 2021 Nov 3.
- Drolet M, Benard E, Perez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3. Epub 2019 Jun 26.
- Sonawane K, Zhu Y, Montealegre JR, Lairson DR, Bauer C, McGee LU, Giuliano AR, Deshmukh AA. Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey. Lancet Public Health. 2020 Sep;5(9):e484-e492. doi: 10.1016/S2468-2667(20)30139-0. Epub 2020 Jul 21.
- Zang S, Zhang X, Qu Z, Chen X, Hou Z. Promote COVID-19 Vaccination for Older Adults in China. China CDC Wkly. 2022 Sep 16;4(37):832-834. doi: 10.46234/ccdcw2022.173. No abstract available.
- Zhang Y, Wang Y, Liu L, Fan Y, Liu Z, Wang Y, Nie S. Awareness and knowledge about human papillomavirus vaccination and its acceptance in China: a meta-analysis of 58 observational studies. BMC Public Health. 2016 Mar 3;16:216. doi: 10.1186/s12889-016-2873-8.
- Xie Y, Su LY, Wang F, Tang HY, Yang QG, Liu YJ. Awareness regarding and vaccines acceptability of human papillomavirus among parents of middle school students in Zunyi, Southwest China. Hum Vaccin Immunother. 2021 Nov 2;17(11):4406-4411. doi: 10.1080/21645515.2021.1951931. Epub 2021 Jul 29.
- Wei Z, Liu Y, Zhang L, Sun X, Jiang Q, Li Z, Wu Y, Fu C. Stages of HPV Vaccine Hesitancy Among Guardians of Female Secondary School Students in China. J Adolesc Health. 2023 Jan;72(1):73-79. doi: 10.1016/j.jadohealth.2022.08.027. Epub 2022 Oct 11.
- Zhang X, Wang Z, Ren Z, Li Z, Ma W, Gao X, Zhang R, Qiao Y, Li J. HPV vaccine acceptability and willingness-related factors among Chinese adolescents: a nation-wide study. Hum Vaccin Immunother. 2021 Apr 3;17(4):1025-1032. doi: 10.1080/21645515.2020.1812314. Epub 2020 Oct 29.
- Zhang X, Liu CR, Wang ZZ, Ren ZF, Feng XX, Ma W, Gao XH, Zhang R, Brown MD, Qiao YL, Geng Q, Li J. Effect of a school-based educational intervention on HPV and HPV vaccine knowledge and willingness to be vaccinated among Chinese adolescents : a multi-center intervention follow-up study. Vaccine. 2020 Apr 29;38(20):3665-3670. doi: 10.1016/j.vaccine.2020.03.032. Epub 2020 Mar 31.
- Wang D, Wu J, Du J, Ong H, Tang B, Dozier M, Weller D, Campbell C. Acceptability of and barriers to human papillomavirus vaccination in China: A systematic review of the Chinese and English scientific literature. Eur J Cancer Care (Engl). 2022 May;31(3):e13566. doi: 10.1111/ecc.13566. Epub 2022 Mar 1.
- Si M, Su X, Jiang Y, Wang W, Zhang X, Gu X, Ma L, Li J, Zhang S, Ren Z, Liu Y, Qiao Y. Effect of an IMB Model-Based Education on the Acceptability of HPV Vaccination Among College Girls in Mainland China: A Cluster RCT. Cancer Control. 2022 Jan-Dec;29:10732748211070719. doi: 10.1177/10732748211070719.
- Si M, Su X, Jiang Y, Wang W, Zhang X, Gu X, Ma L, Li J, Zhang S, Ren Z, Liu Y, Qiao Y. An Internet-Based Education Program for Human Papillomavirus Vaccination Among Female College Students in Mainland China: Application of the Information-Motivation-Behavioral Skills Model in a Cluster Randomized Trial. J Med Internet Res. 2022 Sep 30;24(9):e37848. doi: 10.2196/37848.
- Luk TT, Lui JHT, Wang MP. Efficacy, Usability, and Acceptability of a Chatbot for Promoting COVID-19 Vaccination in Unvaccinated or Booster-Hesitant Young Adults: Pre-Post Pilot Study. J Med Internet Res. 2022 Oct 4;24(10):e39063. doi: 10.2196/39063.
- Lee KY, Dabak SV, Kong VH, Park M, Kwok SLL, Silzle M, Rachatan C, Cook A, Passanante A, Pertwee E, Wu Z, Elkin JA, Larson HJ, Lau EHY, Leung K, Wu JT, Lin L. Effectiveness of chatbots on COVID vaccine confidence and acceptance in Thailand, Hong Kong, and Singapore. NPJ Digit Med. 2023 May 25;6(1):96. doi: 10.1038/s41746-023-00843-6.
- Wilson L, Marasoiu M. The Development and Use of Chatbots in Public Health: Scoping Review. JMIR Hum Factors. 2022 Oct 5;9(4):e35882. doi: 10.2196/35882.
- Almalki M, Azeez F. Health Chatbots for Fighting COVID-19: a Scoping Review. Acta Inform Med. 2020 Dec;28(4):241-247. doi: 10.5455/aim.2020.28.241-247.
- Kobayashi T, Nishina Y, Tomoi H, Harada K, Tanaka K, Matsumoto E, Horimukai K, Ishihara J, Sasaki S, Inaba K, Seguchi K, Takahashi H, Salinas JL, Yamada Y. Corowa-kun: A messenger app chatbot delivers COVID-19 vaccine information, Japan 2021. Vaccine. 2022 Jul 30;40(32):4654-4662. doi: 10.1016/j.vaccine.2022.06.007. Epub 2022 Jun 8.
- Weeks R, Cooper L, Sangha P, Sedoc J, White S, Toledo A, Gretz S, Lahav D, Martin N, Michel A, Lee JH, Slonim N, Bar-Zeev N. Chatbot-Delivered COVID-19 Vaccine Communication Message Preferences of Young Adults and Public Health Workers in Urban American Communities: Qualitative Study. J Med Internet Res. 2022 Jul 6;24(7):e38418. doi: 10.2196/38418.
- 宋祎凡,刘晓雪,尹遵栋,等.2018-2020年中国9-45岁女性人乳头瘤病毒疫苗估算接种率[J].中国疫苗和免疫,2021,27(05):570-575.
- 邱丽蓉,牛战琴.9~14岁女性人乳头瘤病毒疫苗接种现状及其影响因素分析[J].中国生育健康杂志,2022,33(03):262-265.
- 史金晶,张肖肖,郑徽,等.中国大陆青少年家长人乳头瘤病毒疫苗认知度和接受度Meta分析[J].中国疫苗和免疫,2019,25(04):464-470.
- 武丽,马远珠,黄雪萍,等.广东省青少年女性对HPV疫苗知晓及接种意愿的调查研究[J].中国妇幼卫生杂志,2021,12(05):19-23.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FudanU-HPV Chatbot
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV Vaccine
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingHPV Vaccine | HPVUnited States, Puerto Rico
-
University of PittsburghMerck Sharp & Dohme LLCCompletedQuadrivalent HPV Vaccine | Human Papillomavirus VaccineUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedHPV Vaccine KnowledgeUnited States
-
Institut National de la Santé Et de la Recherche...CompletedHPV Vaccine AcceptabilityFrance
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); University of Minnesota; Kaiser PermanenteCompletedHPV Vaccine | Provider Communication Practices | Vaccine Recommendation PracticesUnited States
-
National Institute for Control of Vaccine and BiologicalsUnknownHuman Papillomavirus (HPV) VaccineVietnam
-
University of CincinnatiCompletedHPV Vaccine AcceptabilityUnited States
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedCompletion of Three Dose Series of HPV | Improvement in Vaccine Intervals Between HPV DosesUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI); University of California, Los AngelesCompletedHPV Vaccine | Adolescent Health | Vaccine | Immunization | Reproductive Health | Preventive Health Services | Human Papiloma Virus Vaccine | Health RegistryUnited States
Clinical Trials on Vaccine chatbot that offering HPV vaccine-related information
-
Lake Cumberland District Health DepartmentMerck Sharp & Dohme LLCCompletedHuman PapillomavirusUnited States
-
Kaohsiung Medical UniversityCompletedHealth Services ResearchIndonesia